Exploring novel pharmacological trends: Natural compounds in dry eye disease management.

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

Acta Pharmaceutica Pub Date : 2024-09-14 Print Date: 2024-09-01 DOI:10.2478/acph-2024-0028

Tibor Rák, Adrienne Csutak

{"title":"Exploring novel pharmacological trends: Natural compounds in dry eye disease management.","authors":"Tibor Rák, Adrienne Csutak","doi":"10.2478/acph-2024-0028","DOIUrl":null,"url":null,"abstract":"Dry eye disease (DED) is an ocular condition characterized by altered tear film homeostasis, resulting in symptoms like tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. It affects visual acuity and quality of life and is influenced by age, gender, and environmental factors. The first line of treatment consists of dynamically developing artificial tears, gels, and eyelid sprays, which can be supplemented with natural ingredients for enhanced efficacy. Other therapeutic steps include auto-logous serum tears, anti-inflammatory and immunosuppressive eyedrops, or oral tablets. Management also targets Meibomian gland dysfunction and the ocular surface micro-biome. This article explores various therapeutic approaches, including natural compounds and complementary strategies. Natural compounds, such as vitamins, and herbal substances (e.g., trehalose), offer promising benefits in enhancing tear film stability and ocular surface protection. Apitherapeutic products like manuka honey and propolis exhibit antibacterial and anti-inflammatory properties. Additionally, human tissue-derived solutions, such as auto-logous serum tears and amniotic membrane extracts, hold the potential for ocular surface regeneration. Other strategies, including polyherbal eye drops, liposomal eyelid sprays, and microbiome-supporting solutions offer alternative therapeutic avenues. Moreover, patient education, lifestyle modifications, and interdisciplinary collaboration play crucial roles in DED management, emphasizing the importance of holistic care approaches.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"74 3","pages":"383-404"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/acph-2024-0028","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Dry eye disease (DED) is an ocular condition characterized by altered tear film homeostasis, resulting in symptoms like tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. It affects visual acuity and quality of life and is influenced by age, gender, and environmental factors. The first line of treatment consists of dynamically developing artificial tears, gels, and eyelid sprays, which can be supplemented with natural ingredients for enhanced efficacy. Other therapeutic steps include auto-logous serum tears, anti-inflammatory and immunosuppressive eyedrops, or oral tablets. Management also targets Meibomian gland dysfunction and the ocular surface micro-biome. This article explores various therapeutic approaches, including natural compounds and complementary strategies. Natural compounds, such as vitamins, and herbal substances (e.g., trehalose), offer promising benefits in enhancing tear film stability and ocular surface protection. Apitherapeutic products like manuka honey and propolis exhibit antibacterial and anti-inflammatory properties. Additionally, human tissue-derived solutions, such as auto-logous serum tears and amniotic membrane extracts, hold the potential for ocular surface regeneration. Other strategies, including polyherbal eye drops, liposomal eyelid sprays, and microbiome-supporting solutions offer alternative therapeutic avenues. Moreover, patient education, lifestyle modifications, and interdisciplinary collaboration play crucial roles in DED management, emphasizing the importance of holistic care approaches.

查看原文本刊更多论文

探索新型药理学趋势：天然化合物在干眼症治疗中的应用。

干眼症（DED）是一种以改变泪膜平衡为特征的眼部疾病，会导致泪膜不稳定、高渗透性、炎症和神经感觉异常等症状。它影响视力和生活质量，并受年龄、性别和环境因素的影响。第一线治疗包括动态开发人工泪液、凝胶和眼睑喷雾剂，可添加天然成分以提高疗效。其他治疗步骤包括自体血清泪液、抗炎和免疫抑制眼药水或口服药物。治疗还针对睑板腺功能障碍和眼表微生物群。本文探讨了各种治疗方法，包括天然化合物和辅助策略。天然化合物，如维生素和草本物质（如曲哈糖），在增强泪膜稳定性和眼表保护方面具有广阔的前景。麦卢卡蜂蜜和蜂胶等皮肤治疗产品具有抗菌和消炎特性。此外，源自人体组织的溶液（如自体血清泪液和羊膜提取物）也具有眼表再生的潜力。其他策略，包括多草药眼药水、脂质体眼睑喷雾剂和微生物支持溶液，也提供了其他治疗途径。此外，患者教育、生活方式调整和跨学科合作在 DED 的治疗中发挥着至关重要的作用，强调了整体护理方法的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Pharmaceutica PHARMACOLOGY & PHARMACY-

CiteScore

5.20

自引率

3.60%

发文量

审稿时长

>12 weeks

期刊介绍： AP is an international, multidisciplinary journal devoted to pharmaceutical and allied sciences and contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice. Topics covered are: analytics, biochemistry, biopharmaceutics, biotechnology, cell biology, cell cultures, clinical pharmacy, drug design, drug delivery, drug disposition, drug stability, gene technology, medicine (including diagnostics and therapy), medicinal chemistry, metabolism, molecular modeling, pharmacology (clinical and animal), peptide and protein chemistry, pharmacognosy, pharmacoepidemiology, pharmacoeconomics, pharmacodynamics and pharmacokinetics, protein design, radiopharmaceuticals, and toxicology.